Availability and funding of clinical genomic sequencing globally
Bibliographic Data
| ID | 21881489 |
|---|---|
| Authors | Kimberley A Phillips (0000-0003-0822-4968, University of California, San Francisco, corresponding author), Michael P Douglas (0000-0001-8517-6678, University of California, San Francisco), Sarah Wordsworth (0000-0002-2361-3040, National Institute for Health and Care Research), James Buchanan (0000-0003-2528-0638, National Institute for Health and Care Research), Deborah A Marshall (0000-0002-8467-8008, University of Calgary) |
| Year | 2021 |
| Volume | 6 |
| Issue | 2 |
| Pages | e004415 |
| Publication date | 2021-02-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | BMJ Global Health (JOURNAL) |
| Journal identifiers | ISSN: 2059-7908 • E-ISSN: 2059-7908 |
| Publisher | BMJ (PUBLISHER • GB) |
| DOI | 10.1136/bmjgh-2020-004415 |
| PMID | 33574068 |
| OpenAlex | W3126692631 |
| Language | EN |
| Citations received | 1 |
| References cited | 16 |
The emergence of next-generation genomic sequencing (NGS) tests for use in clinical care has generated widespread interest around the globe, but little is known about the availability and funding of these tests worldwide. We examined NGS availability across world regions and countries, with a particular focus on availability of three key NGS tests—Whole-Exome Sequencing or Whole-Genome Sequencing for diagnosis of suspected genetic diseases such as intellectual disability disorders or rare diseases, non-invasive prenatal testing for common genetic abnormalities in fetuses and tumor sequencing for therapy selection and monitoring of cancer treatment. We found that these NGS tests are available or becoming available in every major region of the world. This includes both high-income countries with robust genomic programmes such as the USA and the UK, and growing availability in countries with upper-middle-income economies. We used exploratory case studies across three diverse health care systems (publicly funded/national (UK), publicly funded/provincial (Canada) and mixed private/public system (USA)) to illustrate the funding challenges and approaches used to address those challenges that might be adopted by other countries. We conclude by assessing what type of data and initiatives will be needed to better track and understand the use of NGS around the world as such testing continues to expand
Biology · Economic growth · Exome sequencing · Genetic testing · Genome · Genomic sequencing · Mutation · Pathology · Private sector · Public health · Cancer Genomics and Diagnostics · Genetic factors in colorectal cancer · Genomics and Rare Diseases · Medicine · Genetics
| Citations per year | 0.5 |
|---|---|
| Citation span | 2024 - 2024 (1) |
| Highly cited | No |